Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 75

1.

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters.

Kalkowska DA, Pallansch MA, Thompson KM.

Epidemiol Infect. 2019 Oct 24;147:e295. doi: 10.1017/S095026881900181X.

2.

Logistical challenges and assumptions for modeling the failure of global cessation of oral poliovirus vaccine (OPV).

Thompson KM, Kalkowska DA.

Expert Rev Vaccines. 2019 Jul;18(7):725-736. doi: 10.1080/14760584.2019.1635463. Epub 2019 Jul 2.

3.

Polio endgame options: will we have the vaccines needed?

Thompson KM.

Lancet. 2019 Jul 13;394(10193):99-100. doi: 10.1016/S0140-6736(19)31294-2. Epub 2019 Jun 4. No abstract available.

4.

Another look at silent circulation of poliovirus in small populations.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

Infect Dis Model. 2018 Jun 9;3:107-117. doi: 10.1016/j.idm.2018.06.001. eCollection 2018.

5.

Characterising the costs of the Global Polio Laboratory Network: a survey-based analysis.

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM.

BMJ Open. 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.

6.

Global certification of wild poliovirus eradication: insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission.

Duintjer Tebbens RJ, Kalkowska DA, Thompson KM.

BMJ Open. 2019 Jan 15;9(1):e023938. doi: 10.1136/bmjopen-2018-023938.

7.

Modeling Undetected Live Poliovirus Circulation After Apparent Interruption of Transmission: Pakistan and Afghanistan.

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM.

Risk Anal. 2019 Feb;39(2):402-413. doi: 10.1111/risa.13214. Epub 2018 Oct 8.

PMID:
30296340
8.

Evaluation of Proactive and Reactive Strategies for Polio Eradication Activities in Pakistan and Afghanistan.

Duintjer Tebbens RJ, Thompson KM.

Risk Anal. 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.

PMID:
30239026
9.

Environmental Surveillance System Characteristics and Impacts on Confidence About No Undetected Serotype 1 Wild Poliovirus Circulation.

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM.

Risk Anal. 2019 Feb;39(2):414-425. doi: 10.1111/risa.13193. Epub 2018 Sep 21.

PMID:
30239023
10.

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine.

Duintjer Tebbens RJ, Thompson KM.

Expert Rev Vaccines. 2018 Aug;17(8):739-751. doi: 10.1080/14760584.2018.1506333. Epub 2018 Aug 9. Review.

11.

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.

Duintjer Tebbens RJ, Hampton LM, Thompson KM.

BMC Infect Dis. 2018 Apr 10;18(1):165. doi: 10.1186/s12879-018-3074-0.

12.

Modeling Poliovirus Transmission in Pakistan and Afghanistan to Inform Vaccination Strategies in Undervaccinated Subpopulations.

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM.

Risk Anal. 2018 Aug;38(8):1701-1717. doi: 10.1111/risa.12962. Epub 2018 Jan 3.

PMID:
29314143
13.

Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine for the Remaining Serotypes.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2017 Jul 1;216(suppl_1):S168-S175. doi: 10.1093/infdis/jix128.

14.

Lessons From the Polio Endgame: Overcoming the Failure to Vaccinate and the Role of Subpopulations in Maintaining Transmission.

Thompson KM, Duintjer Tebbens RJ.

J Infect Dis. 2017 Jul 1;216(suppl_1):S176-S182. doi: 10.1093/infdis/jix108.

15.

Insights from a Systematic Search for Information on Designs, Costs, and Effectiveness of Poliovirus Environmental Surveillance Systems.

Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM.

Food Environ Virol. 2017 Dec;9(4):361-382. doi: 10.1007/s12560-017-9314-4. Epub 2017 Jul 7. Review.

PMID:
28687986
16.

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers.

Duintjer Tebbens RJ, Thompson KM.

Vaccine. 2017 Jul 5;35(31):3823-3833. doi: 10.1016/j.vaccine.2017.05.090. Epub 2017 Jun 9.

17.

Poliovirus vaccination during the endgame: insights from integrated modeling.

Duintjer Tebbens RJ, Thompson KM.

Expert Rev Vaccines. 2017 Jun;16(6):577-586. doi: 10.1080/14760584.2017.1322514. Epub 2017 May 9. Review.

PMID:
28437234
18.

Costs and Benefits of Including Inactivated in Addition to Oral Poliovirus Vaccine in Outbreak Response After Cessation of Oral Poliovirus Vaccine Use.

Duintjer Tebbens RJ, Thompson KM.

MDM Policy Pract. 2017 Mar 1;2(1):2381468317697002. doi: 10.1177/2381468317697002. eCollection 2017 Jan-Jun.

19.

The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management.

Duintjer Tebbens RJ, Thompson KM.

Future Microbiol. 2016 Dec;11:1549-1561. Epub 2016 Nov 10.

20.

Supplemental Content

Loading ...
Support Center